Royalty Pharma PLC - Class A (RPRX) closed at $68.67 on November 18, 2026, unchanged from the previous close, on volume of 2,922,862 shares (30-day average 3,266,930).
Data as of November 18, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Diagonal Call Spread | 20-Nov : 18-Dec-2665 : 67.5 C | 396 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
Analysts’ Top Healthcare Picks: Royalty Pharma (RPRX), Disc Medicine (IRON)
TipRanks (Wed, 18-Nov 8:40 AM ET)
Royalty Pharma to present at the UBS Global Biopharma Conference
Globe Newswire (Thu, 12-Nov 4:15 PM ET)
Royalty Pharma reports third quarter 2026 results
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Royalty Pharma declares fourth quarter 2026 dividend
Globe Newswire (Fri, 16-Oct 8:00 AM ET)
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Globe Newswire (Fri, 9-Oct 8:50 AM ET)
Globe Newswire (Tue, 15-Sep 4:35 PM ET)
Royalty Pharma to present at upcoming investor conferences
Globe Newswire (Wed, 9-Sep 4:05 PM ET)
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
Globe Newswire (Fri, 4-Sep 7:05 PM ET)
Royalty Pharma Raises 2026 Guidance After Double-Digit Growth Across Key Royalty Streams
Market Chameleon (Wed, 5-Aug 5:48 AM ET)
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Royalty Pharma PLC - Class A trades on the NASDAQ stock market under the symbol RPRX.
As of November 19, 2026, RPRX stock price declined to $67.74 with 1,402,639 million shares trading.
RPRX has a beta of 0.03, meaning it tends to be less sensitive to market movements. RPRX has a correlation of 0.00 to the broad based SPY ETF.
RPRX has a market cap of $30.16 billion. This is considered a Large Cap stock.
Last quarter Royalty Pharma PLC - Class A reported $690 million in Revenue and $1.21 earnings per share. This fell short of revenue expectation by $-193 million and exceeded earnings estimates by $.03.
In the last 3 years, RPRX traded as high as $70.37 and as low as $24.05.
The top ETF exchange traded funds that RPRX belongs to (by Net Assets): VXF, VFLO, IWR, VYM, IHE.
RPRX has outperformed the market in the last year with a price return of +74.0% while the SPY ETF gained +9.7%. RPRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +13.9% and +0.6%, respectively, while the SPY returned -6.4% and -6.6%, respectively.
RPRX support price is $67.58 and resistance is $69.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RPRX shares will trade within this expected range on the day.